- Investing Ideas
- /
- South Korean Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
South Korean Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
6
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
6 companies
Yuhan
Market Cap: ₩8.7t
Manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally.
A000100
₩115,100.00
7D
-0.3%
1Y
62.1%
ALTEOGEN
Market Cap: ₩20.7t
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
A196170
₩369,000.00
7D
-6.1%
1Y
112.4%
SK Biopharmaceuticals
Market Cap: ₩8.2t
A pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders.
A326030
₩103,400.00
7D
-1.3%
1Y
23.8%
Seegene
Market Cap: ₩1.2t
Manufactures and sells molecular diagnostics products worldwide.
A096530
₩26,650.00
7D
6.4%
1Y
21.7%
PharmaResearch
Market Cap: ₩3.9t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩375,500.00
7D
2.2%
1Y
216.1%
ST PharmLtd
Market Cap: ₩1.6t
Provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally.
A237690
₩77,100.00
7D
0.7%
1Y
-10.0%